Glycogen Synthase Kinase-3β Is Associated with the Prognosis of Hepatocellular Carcinoma and May Mediate the Influence of Type 2 Diabetes Mellitus on Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Glycogen Synthase Kinase-3β Is Associated with the Prognosis of Hepatocellular Carcinoma and May Mediate the Influence of Type 2 Diabetes Mellitus on Hepatocellular Carcinoma

Published:2014-08-26 Issue:8 Volume:9 Page:e105624
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Qiao Guoliang,Le Yuan,Li Jun,Wang Lianghuan,Shen Feng

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference41 articles.

1. Global cancer statistics;A Jemal;CA Cancer J Clin,2011

2. Surgical resection of hepatocellular carcinoma;JP Duffy;Cancer J,2008

3. Randomized controlled trial of screening for hepatocellular carcinoma;BH Zhang;J Cancer Res Clin Oncol,2004

4. Wnt signaling: complexity at the surface;KM Cadigan;J Cell Sci,2006

5. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes;EJ Henriksen;Curr Drug Targets,2006

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells;Biomarker Research;2024-04-09

2. CircLIFR suppresses hepatocellular carcinoma progression by sponging miR-624-5p and inactivating the GSK-3β/β-catenin signaling pathway;Cell Death & Disease;2022-05-17

3. Diabetes and Cancer: Metabolic Association, Therapeutic Challenges, and the Role of Natural Products;Molecules;2021-04-10

4. mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?;Frontiers of Medicine;2020-11-09

5. GSK-3 in liver diseases: Friend or foe?;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2020-09